1. Characterization of Blebbistatin Inhibition of Smooth Muscle Myosin and Nonmuscle Myosin-2
- Author
-
Huan-Hong Ji, Hai-Man Zhang, Tong Ni, Rong-Na Ma, Aibing Wang, and Xiang-dong Li
- Subjects
0301 basic medicine ,ATPase ,Mutant ,Mutation, Missense ,Biology ,medicine.disease_cause ,Heterocyclic Compounds, 4 or More Rings ,Biochemistry ,law.invention ,Avian Proteins ,Mice ,03 medical and health sciences ,Smooth muscle ,law ,Myosin ,medicine ,Animals ,Humans ,Smooth Muscle Myosins ,Mutation ,Nonmuscle Myosin Type IIB ,Mutagenesis ,Molecular biology ,Cell biology ,030104 developmental biology ,Amino Acid Substitution ,Recombinant DNA ,biology.protein ,Chickens - Abstract
Blebbistatin is a potent and specific inhibitor of the motor functions of class II myosins, including striated muscle myosin and nonmuscle myosin-2 (NM2). However, the blebbistatin inhibition of NM2c has not been assessed and remains controversial with respect to its efficacy with smooth muscle myosin (SmM), which is highly homologous to NM2. To clarify these issues, we analyzed the effects of blebbistatin on the motor activities of recombinant SmM and three NM2s (NM2a, -2b, and -2c). We found that blebbistatin potently inhibits the actin-activated ATPase activities of SmM and NM2s with following IC50 values: 6.47 μM for SmM, 3.58 μM for NM2a, 2.30 μM for NM2b, and 1.57 μM for NM2c. To identify the blebbistatin-resistant myosin-2 mutant, we performed mutagenesis analysis of the conserved residues in the blebbistatin-binding site of SmM and NM2s. We found that the A456F mutation renders SmM and NM2s resistant to blebbistatin without greatly altering their motor activities or phosphorylation-dependent regul...
- Published
- 2017
- Full Text
- View/download PDF